Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Helixor M in Advanced Solid Tumors
NCT03051477Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2017
- Primary completion
- Jan 2021
- Modality
- Botanical Extract, NPI (Non-pharmacological intervention), Immunomodulator
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of viscum album extract in solid tumor, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Number of participants experiencing toxicities at 3 years and Maximum tolerated dose at 2 years. Started Mar 2017; status: completed.
02
Drugs
viscum album extract
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03051477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03051477.